284 research outputs found

    Changes in the pronunciation of Māori and implications for teachers and learners of Māori

    Get PDF
    This paper discusses changes in the pronunciation of Māori and implications for teachers and learners of Māori. Data on changes in the pronunciation of Māori derives from the MAONZE project (Māori and New Zealand English with support from the Marsden fund). The project uses recordings from three sets of speakers to track changes in the pronunciation of Māori and evaluate influence from English. Results from the project show changes in both vowel quality and vowel duration and some evidence of diphthong mergers in pairs such as ai/ae and ou/au, especially amongst the younger speakers. In terms of duration the younger speakers are producing smaller length distinctions between long/short vowel pairs other than /ā, a/. We discuss the implications of such changes for those teaching Māori and for students learning Māori as a subject. These changes raise interesting questions concerning the pronunciation of Māori by future generations

    /u/ fronting and /t/ aspiration in Māori and New Zealand English

    Get PDF
    This article examines the relationship between the frontness of /u/ and the aspiration of /t/ in both Māori and New Zealand English (NZE). In both languages, these processes can be observed since the earliest recordings dating from the latter part of the nineteenth century. We report analyses of these developments for three groups of male speakers of Māori spanning the twentieth century. We compare the Māori analyses with analyses of related features of the speakers' English and of the English of monolingual contemporaries. The occurrence of these processes in Māori cannot be seen simply as interference from NZE as the Māori-speaking population became increasingly bilingual. We conclude that it was the arrival of English with its contrast between aspirated and unaspirated plosives, rather than direct borrowing, that was the trigger for the fronting of the hitherto stable back Māori /u/ vowel together with increased aspiration of /t/ before both /i/ and /u/

    Styles, standards and meaning

    Get PDF
    Abstract Style, in the study of variation and change, is intimately linked with broader questions about linguistic innovation and change, standards, social norms, and individual speakers’ stances. This article examines style when applied to lesser-studied languages. Style is both (i) the product of speakers’ choices among variants, and (ii) something reflexively produced through the association of variants and the social position of the users of those variants. In the context of the languages considered here, we ask “What questions do we have about variation in this language and what notion(s) of style will answer them?” We highlight methodological, conceptual and analytical challenges for the notion of style as it is usually operationalised in variationist sociolinguistics. We demonstrate that style is a useful research heuristic which – when marshalled alongside locally-oriented accounts of, or proxies for “standard” and “prestige”, in apparent time – allows us to describe language and explore change. It is also a means for exploring social meaning, which speakers may have more or less conscious control over

    Comparative Immunogenicity of Na-GST-1 Human Hookworm Vaccine with Synthetic Glucopyranosyl Lipid Adjuvant (GLA) in BALB/c Mice

    Get PDF
    More than 740 million people worldwide are infected with Hookworm. Hookworm infection is most prevalent in the poorest of the poor populations of the world, and has serious health effects. Hookworm infection causes blood loss leading to iron deficiency anemia and protein energy malnutrition, which results in a compromised immune response. Consequently, the target human population suffers from an increased susceptibility to infectious diseases including hookworm infection. We have developed recombinant adult hookworm vaccines against hookworm infection to break this vicious cycle. Toll-like receptor (TLR) 4 agonist are known to boost immune response in healthy and immunocompromised individuals. We believe that co-injecting Synthetic Glucopyranosyl Lipid Adjuvant (GLA) a novel TLR-4 agonist with adult hookworm Na-GST-1 + AlhydrogelÂź vaccine will produce a robust and sustainable immune response in this target human population. Here, we discuss the rationale of using GLA, study designs and the results of the pre-clinical immunogenicity studies of the Human Hookworm Na-GST-1 + AlhydrogelÂź Vaccine in BALB/c mice with and without GLA. We conclude that, GLA enhanced the immunogenicity of co-administered adult hookworm Na-GST-1 + AlhydrogelÂź vaccine, producing a strong anti-Na-GST-1 IgG response. These preclinical results lay the foundation of co-administrating GLA with adult hookworm Na-GST-1 + AlhydrogelÂź vaccine in Phase 1 clinical trial in Brazil

    Potency Testing for NTD Vaccines: Determining Relative Potency for the Na-GST-1 Human Hookworm Vaccine

    Get PDF
    Over the next decade, a new generation of vaccines will target the neglected tropical diseases (NTDs) . The goal of most NTD vaccines will be to reduce the morbidity and decrease the chronic debilitating nature of these often-forgotten infections - outcomes that are hard to measure in the traditional potency-testing paradigm . The absence of measurable correlates of protection, a lack of permissive animal models for lethal infection, and a lack of clinical indications that do not include the induction of sterilizing immunity required us to reconsider the traditional bioassay methods for determining vaccine potency . Owing to these limitations, potency assay design for NTD vaccines will increasingly rely on a paradigm where potency testing is one among many tools to ensure that a manufacturing process yields a product of consistent quality . This potency test is a bioassay using BALB/c mice, which evaluates the immunogenicity of the vaccine at set time interval post manufacture . Herein, we discuss the results of 12 month potency testing of Necator americanus-glutathione-S- transferase-1 (Na-GST-1) vaccine . The Effective Dose 50 (ED50), with its 95% fiducial limits (FL) for each time point was determined along with the Relative Potency with its 95% FL for 3, 6, 9 and 12 months post manufacture . Potency testing has shown that storage at 4° C decreases the ED50 and increases the relative potency of Na-GST-1 vaccine . We proposed that the change in ED50 and relative potency coincide with higher affinity binding of the Na-GST-1 to the AlhydrogelŸ that occurred during storage at 4° C . These preclinical results lay the foundation for moving forward with Phase 1 clinical trial in Brazil

    Vaccination with Human Hookworm Vaccine Necator americanus Aspartic Protease-1 M74 Generates Neutralizing Antibodies and a Potent Immune Response in BALB/c Mice

    Get PDF
    Backgound: Human Hookworm Infection, a neglected tropical disease infects more than 600 million people around the world. Hookworms ingest hemoglobin containing erythrocytes and Necator americanus Aspartic Protease-1 wild type (Na-APR-1wt) a hemoglobinase cleaves hemoglobin to form Heme and Globin. Globin is further digested by other gut enzymes and the nutritional end products are absorbed by the hookworm’s gut wall. Also, Heme which is toxic to hookworm is detoxified by the Necator americanus Glutathione Transferase-1 (Na-GST-1) a detoxification enzyme secreted by the gut of the hookworm. Necator americanus Aspartic Protease-1 M74 (Na-APR-1 M74) is the new vaccine for the Human Hookworm Infection which is currently under pre-clinical development. Na-APR-1 M74 vaccine is an AlhydrogelÂź adjuvanted vaccine containing the mutant form of the Na-APR-1wt. Neutralizing Na-APR-1wt by potent antibodies (IgG) in the vaccinees will block the initiation of the hemoglobin digestion cascade and starve the hookworms from essential nutrition, leading to their death. Here, we report the results of the neutralizing capacity of antibodies and potency (immunogenicity) of Na-APR-1 M74 vaccine in BALB/c mice. Methods: Serum for IgG was generated by vaccinating BALB/c mice twice subcutaneously with Na-APR-1 M74 an enzymatically inactive mutant form of Na-APR-1wt formulated with AlhydrogelÂź. Assessment of neutralizing capacity of IgG was performed using the standard Cathepsin-D protease assay using MOCAc substrate. Dose response (% Inhibition vs Dose) was assessed using linear regression analysis. Potency testing of the Na-APR-1M74 clinical drug product was performed by standard bioassay. Median Effective Dose 50 (ED50) with the 95% fiducial limits (95%FL) was estimated using Probit Analysis (SASÂź 9.3). Also, Relative Potency (RP) was estimated by the methods described in European Pharmacopeia\u27s Chapter 5.3. Results: Five microgram of IgG neutralized 51.06% of the enzymatic activity of 250ng of Na-APR-1wt. An excellent dose response was also observed. ED50 of 14.15ÎŒg (95%FL = 10.47ÎŒg -- 18.93ÎŒg) and 11.46ÎŒg (95%FL = 4.86ÎŒg --27.42ÎŒg) was estimated for time 1 and 7 month post manufacture respectively. RP at 7 months was found to be 1.23 (95%FL = 0.792--1.917). Conclusion: These preclinical results of the Na-APR-1 M74 vaccine lay the foundation for a Phase 1 Clinical Trial in USA and Brazil. This Na-APR-1 M74 vaccine will be subsequently combined with Necator americanus Glutathione transferase-1 (Na-GST-1) vaccine to form a multivalent human hookworm vaccine

    DHODH modulates transcriptional elongation in the neural crest and melanoma

    Get PDF
    Melanoma is a tumour of transformed melanocytes, which are originally derived from the embryonic neural crest. It is unknown to what extent the programs that regulate neural crest development interact with mutations in the BRAF oncogene, which is the most commonly mutated gene in human melanoma1. We have used zebrafish embryos to identify the initiating transcriptional events that occur on activation of human BRAF(V600E) (which encodes an amino acid substitution mutant of BRAF) in the neural crest lineage. Zebrafish embryos that are transgenic for mitfa:BRAF(V600E) and lack p53 (also known as tp53) have a gene signature that is enriched for markers of multipotent neural crest cells, and neural crest progenitors from these embryos fail to terminally differentiate. To determine whether these early transcriptional events are important for melanoma pathogenesis, we performed a chemical genetic screen to identify small-molecule suppressors of the neural crest lineage, which were then tested for their effects on melanoma. One class of compound, inhibitors of dihydroorotate dehydrogenase (DHODH), for example leflunomide, led to an almost complete abrogation of neural crest development in zebrafish and to a reduction in the self-renewal of mammalian neural crest stem cells. Leflunomide exerts these effects by inhibiting the transcriptional elongation of genes that are required for neural crest development and melanoma growth. When used alone or in combination with a specific inhibitor of the BRAF(V600E) oncogene, DHODH inhibition led to a marked decrease in melanoma growth both in vitro and in mouse xenograft studies. Taken together, these studies highlight developmental pathways in neural crest cells that have a direct bearing on melanoma formation
    • 

    corecore